Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis

Shaher Duchi, Haim Ovadia, Elka Touitou*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

We investigated the efficiency of nasal drug administration as a new non-invasive treatment strategy for MS. Glatiramer Acetate (GA) and GA-Cannabidiol (CBD) combination administered in nasal delivery system (NDS) resulted in a statistically significant decrease of clinical scores and inflammatory cytokine expression in experimental autoimmune encephalomyelitis (EAE) mice. Even a suboptimal dose of Prednisolone in NDS was effective in preventing the clinical signs of the disease. Neuron regeneration was observed in the hippocampus of EAE mice treated with GA-CBD in NDS. This work shows that nasal administration improved drug efficiency and stimulates further research for a non-invasive strategy for MS.

Original languageEnglish
Pages (from-to)32-40
Number of pages9
JournalJournal of Neuroimmunology
Volume258
Issue number1-2
DOIs
StatePublished - 2013

Keywords

  • Cannabidiol
  • Experimental autoimmune encephalomyelitis
  • Glatiramer acetate
  • Multiple sclerosis
  • Nasal drug administration
  • Neurogenesis

Fingerprint

Dive into the research topics of 'Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis'. Together they form a unique fingerprint.

Cite this